Research location
Trento
Italy
Advertisement
Research activity in Trento
ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 71 trials and 75 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Trento
71 linked trials · page 2 of 2ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.NCT01774721 · 2013-05-09 · 1 site observation
COMPLETED
The EPIC Trial The Elderly Patient Individualized Chemotherapy TrialNCT03402048 · 2012-07-01 · 1 site observation
UNKNOWN
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)NCT01555710 · 2012-06-08 · 1 site observation
TERMINATED
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate CancerNCT01308567 · 2011-05-05 · 1 site observation
COMPLETED
A Study of Olaratumab (IMC-3G3) in Prostate CancerNCT01204710 · 2010-10-01 · 1 site observation
COMPLETED
A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell CancerNCT01004250 · 2009-10-01 · 1 site observation
COMPLETED
Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast CancerNCT00884143 · 2009-07-01 · 1 site observation
COMPLETED
MOnitoring REsynchronization deviCes and cARdiac patiEntsNCT00885677 · 2009-06-01 · 1 site observation
TERMINATED
ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex TrialNCT00752986 · 2008-12-01 · 1 site observation
TERMINATED
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + PlaceboNCT00538681 · 2007-09-01 · 1 site observation
TERMINATED
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation
COMPLETED
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)NCT00409188 · 2007-01-01 · 1 site observation
COMPLETED
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialNCT00358215 · 2006-06-01 · 1 site observation
COMPLETED
Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBCNCT00236899 · 2005-09-01 · 1 site observation
COMPLETED
Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS StudyNCT00421863 · 2005-02-01 · 1 site observation
COMPLETED
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT00949910 · 2004-11-01 · 1 site observation
COMPLETED
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.NCT00412022 · 2004-03-01 · 1 site observation
UNKNOWN
A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast CancerNCT02748213 · 2002-02-01 · 1 site observation
COMPLETED
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast CancerNCT00045032 · 2001-11-01 · 1 site observation
COMPLETED
Chemotherapy Plus Surgery in Treating Women With Breast CancerNCT00003013 · 1996-10-01 · 1 site observation
COMPLETED
Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically RemovedNCT00003053 · 1994-01-01 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.